[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611776":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":32,"centralContacts":37,"locations":43,"responsibleParty":57,"collaborators":22,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":22,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":22,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":79,"overallStatus":84,"whyStopped":22,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ivonescimab（AK112） Combined With Chemotherapy","EXPERIMENTAL","Preoperative neoadjuvant therapy for 3 cycles. Radical surgery is performed 4-8 weeks after the last dose. Postoperative radiotherapy is determined according to the clinical situation and pathological stage of the patient.\n\nIvonescimab（AK112） can be maintained for a maximum of 1 year. During the study, patients were be followed until disease progression, withdrawal of informed consent, loss of follow-up, or death.",[13,14,15],"Combination Product: Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy","Procedure: Esophagectomy","Other: Sample",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"COMBINATION_PRODUCT","Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy","Ivonescimab（AK112) 20mg\u002Fkg, IV, Day 1; Albumin paclitaxel 260mg\u002Fm2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"PROCEDURE","Esophagectomy","Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.\n\nThe surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.",[9],{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Sample","Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.\n\n5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.\n\nTumour sample will be collected before neoadjuvant therapy and during surgery.",[9],[33],{"name":34,"affiliation":35,"role":36},"Jianan Wang","2nd Affiliated Hospital, School of Medicine, Zhejiang University","STUDY_CHAIR",[38],{"name":39,"role":40,"phone":41,"phoneExt":22,"email":42},"Zixiang Wu, M.D","CONTACT","+8615268156132","zixiang0717@zju.edu.cn",[44],{"facility":45,"status":22,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":22},"The Second Affiliated Hospital of Zhejiang University","Hangzhou","Zhejiang","310000","China","CN",{"type":52,"coordinates":53},"Point",[54,55],120.16142,30.29365,{"lat":55,"lon":54},{"type":58,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100611776","phase-2-neoadjuvant-ivonescimabak112-combined-with-chemotherapy-in-patients-with-resectable-esophageal-squamous-cell-carcinoma-100611776",false,"NCT07244978","Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma","A Prospective, Single-arm, Single-center, Exploratory Study of the Safety and Efficacy of Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. signed informed consent;\n2. patients age 18 to 75 years old\n3. primary resectable, histologically confirmed esophageal squamous cell cancer;\n4. Esophageal squamous cell carcinoma the clinical stage was II-IVA (according to AJCC TNM stage, 8th edition).\n5. ECOG PS 0-1.\n6. No distant metastasis, the diseases could be resectable assessed by thoracic oncologist;\n\nExclusion Criteria:\n\n1. with significant cardiovascular disease;\n2. current treatment with anti-viral therapy or HBV;\n3. Female patients who are pregnant or lactating;\n4. history of malignancy within 5 years prior to screening;\n5. active or history of autoimmune disease or immune deficiency;\n6. signs of distant metastases.","ALL","18 Years","75 Years",{"count":70,"type":71},49,"ESTIMATED","INTERVENTIONAL",[74],"PHASE2","In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased. It is recommended that a treatment strategy be employed that integrates surgery with radiotherapy, chemotherapy, or immunotherapy, in order to enhance overall survival by improving local-regional tumor control and addressing microscopic metastases. Clinical research indicates that combining anti-PD-1\u002FL1 and anti-VEGF antibodies enhances anti-tumor effects in esophageal squamous cell carcinoma. Ivonescimab, a humanized bispecific monoclonal antibody targeting PD-1\u002FVEGF. This single-arm, prospective, exploratory study is planned to evaluate the combination of ivonescimab and chemotherapy in neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the aim of providing new therapeutic options for this condition.",[77,78],"Esophageal Squamous Cell Carcinoma","Neoadjuvant Therapy",[80,81,82,83,77],"ivonescimab","anti-PD-1","anti-VEGF","Neoadjuvant","NOT_YET_RECRUITING","2026-04-21",{"date":87,"type":88},"2026-04-24","ACTUAL",{"date":90,"type":71},"2026-06-01",{"date":92,"type":71},"2032-12-31",{"name":5,"class":6},1]